anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study has been planned to evaluate the efficacy of Lanconone® in enhancing the overall joint health in the population of ≥ 40 years of age during the daily life activities by the reduction of the joint pain and discomfort. Assessment of pain is the primary objective which will be done by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). It is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the severity of osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. The early onset of action (3 days after commencement of the IP administration) for pain relief which was not captured in the past studies, will be captured in the current study by the telephonic assessment of the study subjects. Lequesne et al developed an index of severity for osteoarthritis for the knee which can be used to assess the effectiveness of therapeutic interventions. Unlike the earlier studies, we will use the Lequesne Functional Index (LFI) to assess the extent of joint health degeneration. In relation to OA, elevated levels of hs-CRP have been correlated with symptoms of joint pain and stiffness. Hence, we decided to analyze the hs-crp levels as one of the secondary objectives. Also, the rescue medication consumption has been limited to lower per day consumption compared to earlier studies to avoid the placebo effect influence on the study results. The efficacy of the IP in sustaining the pain relieving effect will be analyzed on day 35, i.e. one week after the end of the treatment.
This case study describes the experience of the German Permanent Working Group of Competence and Treatment Centers for High Consequence Infectious Diseases, known as STAKOB (Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger). STAKOB brings together public health authorities (competence centers) and high-level isolation units (treatment centers) to collaborate on the clinical management of high-consequence infectious diseases (HCIDs) and emerging infectious diseases. The network is coordinated by the Robert Koch Institute, Germany's federal public health institute. The main tasks of STAKOB are to strengthen HCID clinical and public health management and increase expert knowledge on HCID and non-HCID emerging infectious diseases in Germany. STAKOB enables the exchange of knowledge and experiences; development of guidelines on infection prevention and control measures, clinical management, and therapy; and support for the World Health Organization and other outbreak responses internationally. The past years have shown how important the STAKOB network is for Germany-not only in providing critical care for HCID cases but also increasing capacity to support public health and clinical management of emerging infectious disease cases. However, maintaining several high-level isolation units in Germany requires a high commitment of financial, material, and human resources. Due to the rarity of HCID and emerging infectious disease events, maintaining the appropriate level of preparedness and ensuring sufficient investments is an ongoing struggle. Nevertheless, it is essential to have a network ready to react to HCID and non-HCID emerging infectious diseases in times of a changing biosecurity and infectious landscape.
The invention relates to the technical field of functional microorganism screening and application, and particularly provides a novel cheese bacillus paracasei VHProbi F22 strain with a preservation number of CCTCC No: m2019941. The invention also provides application of the lactobacillus paracasei in regulating intestinal immune disorder and removing DPPH free radical and cholesterol degradation. The cheese bacillus paracasei VHProbi F22 has strong tolerance to artificial intestinal gastric juice, does not generate hemolysin, does not dissolve blood cells, is sensitive to common antibiotics such as erythromycin and tetracycline, and has good biosafety; can tolerate higher salinity. The strain has strong antioxidant capacity and can effectively degrade cholesterol. In addition, the hydrophobicity of the cell surface of the strain is 70.61%, and the strain has certain adhesion capability. The Lactobacillus paracasei VHProbi F22 is effective in alleviating symptoms of intestinal immune disorders.
The invention discloses a horse-derived strain of salmonella abortus equi and application thereof in preparation of inactivated vaccines of salmonella abortus equi, belonging to the technical field of biological vaccines. The equine origin strain of salmonella abortus of the invention is named as 20180316.H.AES.G, is preserved in the China general microbiological culture Collection center, and has the culture preservation numbers as follows: CGMCC No. 18341. The equine origin strain of the salmonella abortus of the invention 20180316 H.AES.G has the advantages of good immunogenicity, good culture characteristics and the like, and is inoculated into salmonella enrichment broth, and inactivated by 0.2% v/v formaldehyde after culture to prepare the inactivated vaccine. Experiments prove that after the inactivated vaccine for the salmonella abortus of the horse, which is prepared by the invention, is used for immunizing a mouse, the mouse can be prevented from dying after being attacked by toxin, and the safety is good after the horse is immunized. Therefore, the vaccine has the advantages of safety, low dose immunization and the like. The invention provides an inactivated vaccine for Salmonella abortus equi for the first time, which can be used for preventing abortion caused by Salmonella abortus equi.
The invention belongs to the technical field of pharmaceutical preparation application, in particular to an application of a bile acid chelating agent or/and vitamin D in preparing a drug for preventing and treating a non-alcoholic fatty liver disease. The bile acid chelating agent is polyamine cation exchange resin and comprises cholestyramine, colestipol and the like, and the vitamin D is selected from vitamin D2, vitamin D3, bioactive vitamin D3 and a derivative of the bioactive vitamin D3. The chelating agent and the vitamin D can be medicated either independently or together. The chelating agent and the vitamin D are combined with intestinal bile acid to reduce fat emulsification, absorption of lipid from diets, and deposition of the lipid in a liver. After the chelating agent and the vitamin D are combined with the intestinal bile acid, liver bile acid synthesis is increased, so that endogenous fatty acid synthesis is inhibited. In addition, the active vitamin D and the derivative thereof also can inhibit inflammation, promotes intestinal reabsorption of the bile acid, inhibits the endogenous fatty acid synthesis, and therefore relieves the non-alcoholic fatty liver disease.
PURPOSE:To form a good-quality cured body having no polymn. inhibiting layers on the surface by spraying an inert gas to the surface of a packed or molded dental polymn. curing material and curing the material in this atmosphere. CONSTITUTION:Various kinds of commercially marketed chemical polymn. type or photopolymn. type materials are usable as the polymn. curing material contg. radical polymerizable methacrylate. The inert gas is exemplified by gaseous nitrogen, gaseous argon, gaseous xenon, etc., and the gaseous nitrogen is more preferably used in terms of the influence on living bodies and cost. While the inert gas, such as gaseous nitrogen, is blown to the packed part from a nozzle 4 for spraying connected to a high-pressure gas cylinder housing the inert gas, the curing is progressed with the chemical polymn. if the above- mentioned polymn. curing material 3 is packed directly into the cavity 2, groove, etc., of a tooth by an ordinary method. The material is cured by irradiating the same with light of a prescribed wavelength (450 to 520nm with camphar- quinone or its deriv.) in the case of the photosetting type.
The RESOLVE trial is an open, parallel arm, randomized clinical trial which will be conducted at public-sector HIV clinics in Uganda and South Africa. We will enroll individuals with HIV age 15 and above who have had two HIV-1 RNA viral load results \>1,000 copies/mL while on TLD as first-line antiretroviral therapy and who have been on TLD for at least 12 months. Participants will be randomized using an equal allocation ratio of 1:1:1 across three study arms: a) Standard of Care (regimen guided by genotypic resistance tests and care as per guidelines in Uganda; continuation of TLD and care as per guidelines in South Africa), 2) Individualized Care with regimen choice based on results of genotypic resistance tests and urine tenofovir adherence assays, or 3) Immediate Switch to PI-based second-line ART. Randomization will be stratified by clinic and prior exposure to non-nucleoside reverse transcriptase inhibitors. We will follow participants for one year with study visits at enrollment, Week 24, and Week 48. The primary outcome of interest will be viral suppression to \<50 copies/mL at 48 weeks using the FDA snapshot definition.
Described herein is a nanofibre matrix comprising 100% natural biopolymers selected from polysaccharides and/or proteins with optional functional ingredients for use as cosmetic products. More specifically, nanofibre matrix manufactured by electrospinning methods comprising a dry sheet without containing any preservatives, surfactants, solvents and crosslinkers. To use nanofibre cosmetic products, simply wet skin and then apply the nanofibre to skin. Functional ingredients may be optionally incorporated within the nanofibre matrix during electrospinning to provide different cosmetic effects. Functional ingredients offer skin benefits such as moisturizing, anti-ageing, wrinkle reduction, brightening, antioxidant and acne treatment. Functional ingredients can be essential oil where it is incorporated into nanofibre matrix to provide scent effect to cosmetic products. Functional ingredients can also be natural dye where it is incorporated in nanofibre matrix to make coloured nanofibres. Coloured nanofibres can be used for makeup products such as blush, eye shadow, eyebrow, nail polish, lipstick, contouring and hair dye product. The nanofibre matrix comprising 100% natural biopolymers with or without functional ingredients can be processed to assorted shapes or easily cut by consumers for using on different areas of skin for different purposes.
Infants whose mothers have been immunized during pregnancy with Tdap vaccine. Infants will receive three doses of Pertussis-containing vaccine (with 28 days interval starting at two months of age).
The safety and efficacy of HEMLIBRA have been established in pediatric patients. Use of HEMLIBRA in pediatric patients with hemophilia A is supported by two randomized trials (HAVEN 1 and HAVEN 3) and two single-arm trials (HAVEN 2 and HAVEN 4). All clinical trials included pediatric patients in the following age group: 47 adolescents (12 years up to less than 18 years). Only HAVEN 2 included pediatric patients in the following age groups: 55 children (2 years up to less than 12 years) and five infants (1 month up to less than 2 years). No differences in efficacy were observed between the different age groups [see Clinical Studies (14)].

The steady-state plasma trough concentrations of emicizumab-kxwh were comparable in adult and pediatric patients older than 6 months at equivalent weight-based doses. Lower concentrations of emicizumab-kxwh were predicted in pediatric patients less than 6 months old [see Clinical Pharmacology (12.3)]. 

In general, the adverse reactions in HEMLIBRA-treated pediatric patients were similar in type to those seen in adult patients with hemophilia A [see Adverse Reactions (6.1)].
The pancreatic innervation undergoes dynamic remodeling during the development of pancreatic ductal adenocarcinoma (PDAC). Denervation experiments have shown that different types of axons can exert either pro- or anti-tumor effects, but conflicting results exist in the literature, leaving the overall influence of the nervous system on PDAC incompletely understood. To address this gap, we propose a continuous mathematical model of nerve-tumor interactions that allows in silico simulation of denervation at different phases of tumor development. This model takes into account the pro- or anti-tumor properties of different types of axons (sympathetic or sensory) and their distinct remodeling dynamics during PDAC development. We observe a "shift effect" where an initial pro-tumor effect of sympathetic axon denervation is later outweighed by the anti-tumor effect of sensory axon denervation, leading to a transition from an overall protective to a deleterious role of the nervous system on PDAC tumorigenesis. Our model also highlights the importance of the impact of sympathetic axon remodeling dynamics on tumor progression. These findings may guide strategies targeting the nervous system to improve PDAC treatment.
Myofascial pain syndrome is a common non-articular musculoskeletal chronic pain which has not been yet fully understood. It is characterized by myofascial trigger point. This trigger point is clinically classified as active or latent. Some studies have demonstrated the potential relevance of latent trigger point. In fact, its presence may cause muscle activation pattern alterations, increase nociceptive sensitivity and cause sympathetic activity alterations. Nevertheless, the vast majority of individuals, even asymptomatic, have latent trigger point. High prevalence of myofascial trigger points subsists at cervical and scapular regions.

There is few data regarding myofascial trigger point physiopathology. Furthermore, a diversity of therapeutic interventions consisting of trigger point inactivation and interruption of the vicious cycle is suggested in literature. Nevertheless, the effectiveness of these different interventions in trigger points and the duration of the effects are not yet fully clarified.
Four points: (1) On the lateral thigh, between the vastus lateralis and biceps femoris, the midpoint of the popliteal stria, and the highest point of the greater trochanter. (2) On the lateral side of the calf, beside the level of Zusanli, and at the lateral edge of the tibia. (3) On the fibular side of the calf, the midpoint of the stomach meridian, and the bile meridian, 3 cm above the tip of the lateral malleolus and in front of the hanging bell. (4) On the lateral side of the calcaneus, and the servant enters the midpoint of the line connecting the posterior edge of the calcaneus at the same level. The 0.30×25-mm filiform needles are inserted straight for 3-5 mm at the points, the needles can stand without Deqi. The auxiliary needle will be inserted and electroacupuncture will be connected (same as in the other group). The internal wire of the electroacupuncture instrument will be interrupted, no current passed through. The treatment time is the same as the other two groups.
The prescribed dose is 50 Gy in 10 fractions. The total dose can be reduced to 40 Gy and the total number of fractions can be reduced to 8 fractions in non-spine metastases to achieve the normal tissue constraints.
PURPOSE: A disposable pigment article used for semi-permanent make up is provided to improve sanitation and safety and to conveniently finish post-processing. CONSTITUTION: A disposable pigment article used for semi-permanent make up comprises an absorbent sheet(100) with improved absorption and a semi-permanent pigment(200) which is spread on the absorbent sheet and is absorbed. In an operation, the end of a needle contacts the absorbent sheet and a pigment is adhered to the end of the needle. The absorbent sheet is inserted into a disposable pouch(300) and is sealed. A cutting line is formed on one side of the pouch. The absorbent sheet is made of one selected from gauze, micro fiber, pulp, absorbent cotton, and non-woven fabric.
PURPOSE:To provide an external skin agent containing an asparagus extract having improved penetrability into the skin and remarkably increased skin- beautifying effect. CONSTITUTION:The objective agent contains (A) an asparagus extract produced by extracting the stalk, rhizome, leaf, flower, etc., of asparagus with a proper solvent at room temperature or under heating and (B) a phospholipid, e.g. natural phospholipid extracted from animals and vegetables (e.g. yolk and soybean) or microorganisms (e.g. E.coli), its hydrogenated product or synthetic phospholipid. The amount of the component A is 0.0001-10.0wt.%, preferably 0.01-5.0wt.% (in terms of dried solid component) and that of the component B is 0.05-20wt.%, preferably 0.05-5wt.%. The external agent for skin may be compounded, in addition to the above essential components, with conventional external skin agent components such as aqueous component, powder, surfactant, oiliness agent, humectant, alcohol, pH-modifier, antiseptic agent, pigment, antioxidant, ultraviolet absorber, thickener, perfume and cosmetic component.
PURPOSE: An anticancer composition containing a Rhodiola sachalinensis extract exhibiting anticancer activity for suppressing proliferation of cancer cells is provided. It inhibits a topoisomerase enzyme and thus is expected to have inhibiting activity against cancer. CONSTITUTION: The pharmaceutical composition contains 0.01 to 80% by weight of a Rhodiola sachalinensis extract, based on the total weight of the composition. The Rhodiola sachalinensis extract is prepared by extracting Rhodiola sachalinensis in a polar solvent with a single reflux cooler, concentrating under reduced pressure, fractioning with a nonpolar solvent such as chloroform, ethylacetate and ether and then carrying out silica gel column chromatography or TLC. The purified fraction has Rf values of 0.50 to 0.60 on TLC. The polar solvent is water, methanol, ethanol or a mixture thereof.
Methods are provided for diagnosing, prognosing, and treating cancers expressing SSTR2, in particular cancers of the head and neck, such as skull base malignancies, head and neck cancers and brain cancers, such as nasopharyngeal cancer and olfactory neuroblastoma. Provided is a non-invasive imaging method, where an imaging agent is administered to an individual with a tumor; where said imaging agent is then quantified within the tumor using PET-CT imaging to provide an indirect measurement of somatostatin receptor expression and to serve as a prognostic biomarker and companion diagnostic biomarker for treatment stratification in sinonasal cancers. Also provided are methods to directly measure SSTR2 expression from biopsied tumors. These methods robustly identify which patients will have increased rates of survival based on indirect and/or direct measurements of the level of expression of somatostatin receptors in tumors. In some embodiments, prognostic power of the non-invasive imaging method can be further increased by utilizing immunohistochemical analysis of tumor biopsies. In some embodiments, the methods further comprise selecting a treatment regimen for the individual based on the analysis.
Tirzepatide will be administered subcutaneously in the stomach, upper arm, or thigh, rotating injection sites with each dose. Administer once weekly at any time of day, with or without meals. Start with an initial dosage of 2.5 mg. After 4 weeks, increase to 5 mg weekly. Further increases may be made in 2.5 mg increments after at least 4 weeks on the current dose, aiming for a target of 15 mg (i.e., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). Consider treatment tolerability when selecting the maintenance dose. If not tolerated, consider the next lower maintenance dose. Recommended maintenance doses are 5 mg, 10 mg, or 15 mg, with 5 mg as the lowest evaluable dose. The 2.5 mg dose is not a maintenance dose. The maximum allowed dosage is 15 mg once weekly.
The invention discloses a Chinese medicine formulation for curing chronic pharyngitis. The Chinese medicine considers that chronic pharyngitis belongs to wind-heat throat impediment, and lung Yin deficiency is most seen in clinic. Therefore, the Chinese medicine formulation selects raw materials from the Chinese medicines which have the functions of clearing away heat and toxic materials, reducing swelling, removing stasis, nourishing yin and moistening lung. The raw materials contain nauclea offcinalis, chinese leontopodium root, bushy sophorae, fructus forsythiae, aromatic madder, arctium fruit, anemarrhena, root of large-flowered skullcap, caulis piperis kadsurae, radix scrophulariae, tuber of dwarf lilyturf, and glehnia root. Then the raw materials are cooked to make a decoction. Through our hospital clinical test, the total effective ratio arrives 95.2%, which is obviously better than the comparative group, therefore the Chinese medicine formulation is worthy for being popularized.
Sertraline hydrochloride Oral Concentrate contains 20 mg/mL of sertraline (as the hydrochloride) as the active ingredient and 12% alcohol. Sertraline hydrochloride Oral Concentrate must be diluted before use. Just before taking, use the dropper provided to remove the required amount of sertraline hydrochloride Oral Concentrate and mix with 4 oz (1/2 cup) of water, ginger ale, lemon/lime soda, lemonade or orange juice ONLY. Do not mix sertraline hydrochloride Oral Concentrate with anything other than the liquids listed. The dose should be taken immediately after mixing. Do not mix in advance. At times, a slight haze may appear after mixing; this is normal. Note that caution should be exercised for patients with latex sensitivity, as the dropper dispenser contains dry natural rubber.

Sertraline hydrochloride Oral Concentrate is contraindicated with ANTABUSE (disulfiram) due to the alcohol content of the concentrate.
Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
In some embodiments, the present disclosure pertains to compositions for nucleic acid delivery into cells. In some embodiments, the composition comprises: (1) a cationic polymer unit comprising a plurality of polymeric arms, where the plurality of polymeric arms comprise poly(aspartic acid) derivatives; and (2) a nucleic acid associated with the cationic polymer unit. In some embodiments, the cationic polymer unit comprises a linker covalently associated with the plurality of polymeric arms. In some embodiments, the cationic polymer unit has a dendritic shape. In some embodiments, the cationic polymer unit has a star-like shape. In some embodiments, the cationic polymer unit is biodegradable. Further embodiments of the present disclosure pertain to methods of delivering a nucleic acid into cells by introducing into the cells one or more of the compositions of the present disclosure.
As per preceding commendation, Rivermead Mobility Index will be translated into Urdu language from its English version and adapted culturally in Pakistan. Among Stroke population, Rivermead Mobility Index will be conducted in 50 patients recruited by convenience sampling technique under the pre-defined inclusion and exclusion criteria after signing consents forms. For testing inter-observer reliability and intra-observer reliability of Rivermead Mobility Index, Barthel Index and Functional Independence Measure will be administrated by two observers, on the same day, with a time interval of 2 hours between 1st and 2nd conduction. As for the 3rd conduction, it will be carried out after seven days by the first observer, for intra-observer assessment. Statistical Package of Social Sciences software version 24 has been used for the purpose of data entry and analysis. Internal consistency will be assessed by using an intra-class correlation coefficient. The Rivermead Mobility Index will be evaluated for content validity, construct validity, criterion validity and responsiveness.